Compound profile · Recovery research

Tesamorelin

A growth-hormone-releasing peptide - and the one here with a genuine FDA-approved track record.

Tissue research METS verified
StatusResearch use only
BPC-157
BPC-157
Dhs. 300.00
Shop now
01

The approved GHRH.

Tesamorelin is a GHRH analog with something most peptides here lack: a full FDA approval, for reducing excess visceral fat in HIV-associated lipodystrophy. That gives it a real human-trial backbone.

01
Approved use
FDA-approved (Egrifta) to reduce visceral abdominal fat in HIV lipodystrophy.
02
Visceral-fat selective
Trials show preferential loss of deep abdominal fat.
03
Beyond the label
Studied for liver fat and cognition in ageing.
Primary structure
GHRH analog (44-aa)
Stabilised GHRH · 44 amino acids
Calculate your reconstitution dosage →
03

At a glance

44
Amino acids
Egrifta
Approved brand
GHRH-R
Target
04

Where the research focuses.

01
Visceral fat

Its approved use - reducing deep abdominal fat, shown in controlled trials.

02
Liver fat / NAFLD

Studied for reducing liver fat, with promising trial signals.

03
Cognition (ageing)

Examined for cognitive effects in older adults via GH/IGF-1.

04
GH / IGF-1 support

Raises the body's own GH in a relatively physiological way.

05

GHRH with a record.

Tesamorelin raises the body's own GH through the GHRH receptor, and its visceral-fat effect is backed by randomised controlled trials - unusual depth for this category.

Its approval is specific, but the underlying human data make it one of the better-evidenced GH-axis compounds.

06

Strength of the evidence.

Tier 01
Strongest support
  • FDA approval for HIV lipodystrophy
  • Visceral-fat reduction in RCTs
  • GHRH-receptor mechanism established
Tier 02
Moderate support
  • Liver-fat reduction signals
  • Cognitive research in ageing
Tier 03
Emerging / unverified
  • General anti-ageing positioning
  • Long-term off-label use
07

How it works

01
GHRH receptor

Stimulates pituitary GH release physiologically.

Established
02
Visceral fat

Preferentially mobilises deep abdominal fat.

RCT-backed
03
IGF-1 axis

Raises IGF-1 within a controlled range.

Clinical
04
Tolerability

Generally well tolerated; injection-site and joint effects reported.

Documented
08

How it moves through the system

AdministrationPeakHalf-lifeCleared
Peak 50% Cleared
~0.5–1 h
Onset to peak
~25–40 min
Half-life
hours
Largely cleared
Curve shape is illustrative; figures reflect pharmacokinetics reported in research - rapid local metabolism, figures from animal IV/IM data.
09

Reconstitution calculator

How much diluent to mix into the vial, and the concentration that results. The suggested volume reaches a clean working stock; the calculator does the arithmetic from figures you enter. These describe solution preparation for research handling — not instructions for use in humans or animals.

Suggested reconstitution Reconstitute the 10 mg vial with 2 mL bacteriostatic water → 5.0 mg/mL (5000 mcg/mL)
Concentration—
Volume / aliquot—
U-100 units—
Aliquots / vial—
Concentration = compound ÷ diluent. Volume per aliquot = target ÷ concentration. U-100 units are a volume readout (1 mL = 100 units). Figures are for research solution preparation only — not instructions for use in humans or animals.
010

Signs of a quality compound

Lyophilised cake or powder
A fine, fluffy white cake — not oily, clumped or discoloured.
Clear reconstitution
Dissolves to a clear, colourless solution with no visible particles or cloudiness.
Batch-specific COA
Independent HPLC purity and mass-spec identity for the exact lot — not a recycled generic PDF.
Intact seal & vacuum
Sealed flip-top vial under vacuum; correct fill; legible batch and storage marking.
Walk away if…
No COA, oily residue, off-colour, partial vacuum, or purity claims with no independent test behind them.
Suspiciously cheap
Pricing far below the market for a well-tested compound usually means skipped testing or underfilled vials.
Regulatory & status
A genuine drug.

Tesamorelin is FDA-approved (Egrifta) for a specific indication; other uses are off-label or research. It is prohibited in competitive sport. Among the GH-axis compounds here, it has the strongest human evidence base.

Status
FDA-approved (Egrifta)
Evidence
RCT-backed visceral-fat data
Other use
Off-label / research
Anti-doping
Prohibited in sport (WADA)
Research handling
Important notices
  • For research purposes only
  • Not for human consumption
  • Not FDA approved
  • Consult a qualified professional
Important

For research use only. Not for human consumption. Apex Academy is an educational reference describing findings reported in published and preclinical literature. Nothing here is medical advice, a protocol, or a recommendation to administer any compound to humans or animals. Many compounds described are investigational and are not approved by the FDA or other regulators for the prevention, treatment, or cure of any condition. Their long-term safety and pharmacokinetics remain incompletely characterized. Dose ranges, where shown, describe quantities used in cited research models - not instructions for use. Consult a qualified, licensed professional before making any health decision.